Judge allows Neurim to seek additional damages in patent suit over insomnia drug

Ben Mee 2020-12-14 3:18 pm By Miklos Bolza | Sydney

Please login to bookmark

Neurim Pharmaceuticals can seek limited additional damages in a patent infringement case relating to its insomnia drug Circadin, after a judge granted a mid-trial bid to amend its pleadings against Generic Partners and Apotex.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au